Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus.
about
Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft.GAS6 receptor status is associated with dormancy and bone metastatic tumor formationIncreased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis.Identification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm rupture.Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthmaGrowth Arrest-Specific 6 Protein in Patients with Sjögren Syndrome: Determination of the Plasma Level and Expression in the Labial Salivary GlandIdentification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasisGrowth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure.Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancerCirculating growth arrest-specific protein 6 levels are associated with erythropoietin resistance in hemodialysis patients.Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity.Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activityHeightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE.Effect of GAS6 and AXL Gene Polymorphisms on Adiposity, Systemic Inflammation, and Insulin Resistance in Adolescents.Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activityO death where is thy sting? Immunologic tolerance to apoptotic self.Promising biomarkers for systemic lupus erythematosus.Incomplete clearance of apoptotic cells in systemic lupus erythematosus: pathogenic role and potential biomarker.Increased Mer and Axl receptor tyrosine kinase expression on glomeruli in lupus nephritis.Diminished soluble levels of growth arrest specific protein 6 and tyrosine kinase receptor Axl in patients with rheumatoid arthritis.Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis.Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus.Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus.Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behçets disease.Soluble TAM receptor tyrosine kinases in rheumatoid arthritis: correlation with disease activity and bone destruction.Recombinant Gas6 augments Axl and facilitates immune restoration in an intracerebral hemorrhage mouse model.Antiphospholipid Antibodies Inhibit Trophoblast Toll-like Receptor and Inflammasome Negative Regulators.GAS6 intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy.Plasma growth arrest-specific protein 6 levels in premenopausal and postmenopausal women: the role of endogenous estrogen.GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis.
P2860
Q34473426-14678240-E8E8-408B-9F7A-84B2924952EDQ34700694-F24C7FBD-7EBE-41CB-8C51-C0C211C2391CQ35093012-01CC7991-A6F5-4523-939F-56FA61B75D8EQ35222509-A0E3ABCA-44FB-442A-A4B7-F52A45DF7F07Q35872028-03F4C279-6B88-404E-997A-D8738BADE157Q36133208-086EDBBE-01FC-4C52-A135-160B5C1AA864Q36340889-733297E3-DAFE-4628-9366-2D7E0BA560ADQ36389223-68C5FEEA-F5A9-4116-83CD-FF7ED71308BFQ36413157-FB489CE1-352F-438F-BF51-7D16C73E3ED8Q36456252-ABBDF48B-80EA-454D-8F29-DF3C73DB0D33Q36633215-B75134AA-7346-4399-B6F6-ADF8EF167705Q36903351-7C788FF0-54B2-46CD-BEDC-738853E4950BQ37541225-99BB8132-D511-4D94-A1C0-C5C6D7B61AD0Q37627863-4D009D7E-1660-4A43-9FE1-CA5DE229457EQ37690725-1E70D5A2-D084-41FF-AE7A-BBFC8D27DC95Q38078769-06C25979-27E4-4346-80A0-AAC3ECEB1627Q38149960-EB1DAA8E-40A2-422D-B07B-CBB3AA92838AQ38425946-7220B842-668B-4FF7-8479-48C1C3F2C66DQ38996188-387ED538-B913-4BE1-A3EB-3E6AF3418C8BQ39215790-153B7217-288B-4EC8-934C-7642DD2EBB27Q40193396-9D30409F-9495-4801-8CDC-20B585674A12Q42134678-2EAFD043-D33F-4301-B8A6-7810C71A35CEQ45976427-3509F8B2-DEED-4E77-9A99-A71EC34281C6Q46346251-05EFBC9D-8AE2-49E3-83B6-9AE1FD44A50BQ48284666-02C0DDC9-84D5-48D8-A7EC-322186B1B245Q48634442-FC45A39D-A6CB-41F6-8416-B853D484A094Q49998565-10CD4AC1-2454-4760-9AE3-81470DDC1D38Q52951926-72A9C344-5DF8-426C-B7C0-647CAAED9911Q53060301-FBE7578E-C6BA-4650-96E0-F8BE4A1BEE9DQ55101698-0C613FF6-F4BD-42B7-BFFF-4675EF64D455
P2860
Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@ast
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@en
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@nl
type
label
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@ast
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@en
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@nl
prefLabel
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@ast
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@en
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@nl
P2093
P2860
P356
P1433
P1476
Plasma concentrations of Gas6 ...... systemic lupus erythematosus.
@en
P2093
Anders A Bengtsson
Andreas Jönsen
Björn Dahlbäck
Carl Ekman
Gunnar Sturfelt
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEQ459
P577
2011-01-28T00:00:00Z